Provan et al. large scandinavian registry study: 🫁ILD risk in RA & PsA initiating b/tsDMARDs HR ILD RA=10 HR ILD PsA=5 No increase risk w/ MTX and b/tsDMARDs but RA HR ILD 1.7 RTX vs. ETA: confounding by indication? https://t.co/CF1ysNkQxU OP0006 #EULAR23 @Rheumnow https://t.co/DgDE1uFeUs

• EULAR Abstract Archive

#EULAR2023 #OP0051 4-year Pooled Analyses of 3 x Anifrolumab RCTs in #lupus (inc. LTE) showed: - LLDAS was attained earlier & more cumulative time was spent in LLDAS in anifrolumab compared to placebo groups Assuring longer-term data *sorry photos weren’t permitted @RheumNow

Autoimmune disease diagnoses slowly on the rise, despite reduced smoking - but that’s now 10% of the population, & many patients have more than one. Most are lifelong. Surely this needs more investment?? CPRD data from the UK #EULAR2023 OP0007 @RheumNow https://t.co/7NGF5YaE9z https://t.co/m6SaibqmEq

• https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00457-9

https://t.co/0FsCCOP17E OP0044 #EULAR23 @RheumNow https://t.co/pl0AnGUAw1

• EULAR Abstract Archive

Scandinavian RA registry study shows reassuring data on CV risk in RA🫀 Acute Coronary Syndrom incidence rates are similar in RA pts achieving remission & general pop & is similar whether RA pts reach remission using MTX or TNFi. https://t.co/wBDZtaTVba OP0038 #EULAR23 @Rheumnow https://t.co/JLdbYF49xF

• EULAR Abstract Archive

Data from combined big Scandinavian population registries looking at both RA and PsA, ILD development, & MTX exposure Here’s the ILD risk for methotrexate. Can we stop this MTX misinformation? No more besmirching a really useful drug for our patients #EULAR2023 OP0006 @RheumNow https://t.co/7swqAYchDC

Interstitial lung disease in RA and PSA in b/tsDMARD treated patients with MTX - there is no increased risk of developing ILD above the background risk of RA and PsA vs general population Sella Aarrestad Provan Abst#OP0006 @RheumNow https://t.co/yJsrmraeZ5

Comorbidities and metabolic burden in PsA: -Occur EARLY -Early PsA pts > multiple comorbidities & > CV morbidity vs. age-matched early RA pts Independent of BMI & obesity Time to address these as part of dis pathogenesis in PsA https://t.co/qOiGHn2eZT OP0066 #EULAR23 @Rheumnow https://t.co/lK7MbeMybO

• EULAR Abstract Archive

AxSpA can be unequivocally diagnosed in the first 2 years of onset of chronic back pain with 30% definite with HLA-B27+ and imaging being the key SpA features from the SPACE cohort by Mary Lucy Marques, Abst #OP0005 @RheumNow https://t.co/m5umD00hDf

With all the benefits of MRI and expert rheumatologists, do our diagnoses of axSpA stick, two years later? Overwhelmingly yes, but sometimes we do actually have to change our minds. Beware the set and forget for our clinical diagnoses SPACE cohort #EULAR2023 OP0005 @RheumNow https://t.co/AN6XzqKlv3

New benefit/risk outlook 👀 on ORAL surveillance 2 subgrps: 🟢RA w/ no previous Hx of atherosclerotic CV dis = TOFA at least as good as TNFi AND risk of MACE is comparable 🛑RA w/ HxASCVD = efficacy TOFA = TNFi AND > risk of MACE https://t.co/VOxNQSoyY4 OP0043 #EULAR23 @Rheumnow https://t.co/m98eSMG03U

• EULAR Abstract Archive

#EULAR2023 Abstr #OP0048 What happened if we taper steroid in #lupus patients who are Serologically Active Clinically Quiescent? A cohort study in Asia showed: - Tapering was NOT associated with subsequent flare - Tapering reduced damage in those on =>5mg/day @RheumNow https://t.co/Q6GiaSCgV6

Improving access and education to SLE patients using the Lupus 100 project which uses native language covering 95% of the European population to provide high quality and accurate information for patients by Zoe Karakla-Mitsakou Abst#OP0004 @RheumNow https://t.co/mWRiZt7uGy

Great patient-driven initiative to get accurate and relevant lupus information to SLE patients. Avoid misinformation and check it out in your language at https://t.co/R2ydvDasFY Congratulations @LupusEurope! #EULAR2023 OP0004 @RheumNow https://t.co/S4sgy5dnro

• Lupus 100 – lupus100

Leiden arthritis clinic: 1000+ pts w/ RA & high BMI associated w/ < MRI-detected osteitis at dis onset but NOT synovitis RA w/ overweight/obesity 25% < MRI-detected erosive progression at 2 yrs More marked in ACPA+ pts Is leptin the missing link? 🤓 OP0039 #EULAR23 @Rheumnow https://t.co/RRSV9VlRtn